Antibody-modified T cells: CARs take the front seat for hematologic malignancies - PubMed (original) (raw)
Review
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
Marcela V Maus et al. Blood. 2014.
Abstract
T cells redirected to specific antigen targets with engineered chimeric antigen receptors (CARs) are emerging as powerful therapies in hematologic malignancies. Various CAR designs, manufacturing processes, and study populations, among other variables, have been tested and reported in over 10 clinical trials. Here, we review and compare the results of the reported clinical trials and discuss the progress and key emerging factors that may play a role in effecting tumor responses. We also discuss the outlook for CAR T-cell therapies, including managing toxicities and expanding the availability of personalized cell therapy as a promising approach to all hematologic malignancies. Many questions remain in the field of CAR T cells directed to hematologic malignancies, but the encouraging response rates pave a wide road for future investigation.
Figures
Figure 1
Therapeutic approaches to overcome immune tolerance to tumors. Cytokines and vaccines can be used to augment natural T-cell responses to tumor. Antibodies targeting negative regulatory molecules such as programmed death 1 (PD-1) and cytotoxic T-cell lymphocyte-associated antigen 4 (CTLA-4) can be infused to release the brakes on natural T cells responsive to tumor. Chemotherapy can reduce immune suppressive cells such as Tregs and myeloid-derived suppressor cells (MDSC) in addition to its direct effect on the tumor cells. Adoptive T-cell transfer strategies using clonally expanded cytotoxic T cells or T cells engineered to express TCRs or CARs are being tested.
Figure 2
Chimeric antigen receptors. CARs target surface antigens in an MHC-independent fashion and consist of an ectodomain, hinge domain, transmembrane domain, and endodomain. The initial trials tested first-generation CARs that have a single cytoplasmic domain. Current trials are testing second- and third-generation CARs that have combinations of signaling domains.
Similar articles
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.
Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, Kaplan RN, Patterson GH, Fry TJ, Orentas RJ, Mackall CL. Long AH, et al. Nat Med. 2015 Jun;21(6):581-90. doi: 10.1038/nm.3838. Epub 2015 May 4. Nat Med. 2015. PMID: 25939063 Free PMC article. - Chimeric antigen receptor-modified T cells: CD19 and the road beyond.
Salter AI, Pont MJ, Riddell SR. Salter AI, et al. Blood. 2018 Jun 14;131(24):2621-2629. doi: 10.1182/blood-2018-01-785840. Epub 2018 May 4. Blood. 2018. PMID: 29728402 Free PMC article. Review. - Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies.
Davila ML, Bouhassira DC, Park JH, Curran KJ, Smith EL, Pegram HJ, Brentjens R. Davila ML, et al. Int J Hematol. 2014 Apr;99(4):361-71. doi: 10.1007/s12185-013-1479-5. Epub 2013 Dec 6. Int J Hematol. 2014. PMID: 24311149 Free PMC article. Review. - State of the art in CAR T cell therapy for CD19+ B cell malignancies.
Frigault MJ, Maus MV. Frigault MJ, et al. J Clin Invest. 2020 Apr 1;130(4):1586-1594. doi: 10.1172/JCI129208. J Clin Invest. 2020. PMID: 32235098 Free PMC article. Review. - CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.
Park JH, Geyer MB, Brentjens RJ. Park JH, et al. Blood. 2016 Jun 30;127(26):3312-20. doi: 10.1182/blood-2016-02-629063. Epub 2016 May 20. Blood. 2016. PMID: 27207800 Free PMC article. Review.
Cited by
- The Biological Significance of Trogocytosis.
Agbakwuru D, Wetzel SA. Agbakwuru D, et al. Results Probl Cell Differ. 2024;73:87-129. doi: 10.1007/978-3-031-62036-2_5. Results Probl Cell Differ. 2024. PMID: 39242376 - In vivo manufacture and manipulation of CAR-T cells for better druggability.
Hou R, Zhang X, Wang X, Zhao X, Li S, Guan Z, Cao J, Liu D, Zheng J, Shi M. Hou R, et al. Cancer Metastasis Rev. 2024 Sep;43(3):1075-1093. doi: 10.1007/s10555-024-10185-8. Epub 2024 Apr 9. Cancer Metastasis Rev. 2024. PMID: 38592427 Review. - Riboswitch-controlled IL-12 gene therapy reduces hepatocellular cancer in mice.
Düchs MJ, Kratzer RF, Vieyra-Garcia P, Strobel B, Schönberger T, Groß P, Aljayyoussi G, Gupta A, Lang I, Klein H, Morilla SM, Hopf S, Park J, Kreuz S, Klugmann M, Igney FH. Düchs MJ, et al. Front Immunol. 2024 Mar 15;15:1360063. doi: 10.3389/fimmu.2024.1360063. eCollection 2024. Front Immunol. 2024. PMID: 38558809 Free PMC article. - scRNA-Seq and Bulk-Seq Analysis Identifies S100A9 Plasma Cells as a Potentially Effective Immunotherapeutic Agent for Multiple Myeloma.
Long X, Li F, Tang S, Liu J, Fu Y, Feng Y. Long X, et al. J Inflamm Res. 2024 Mar 9;17:1527-1548. doi: 10.2147/JIR.S452062. eCollection 2024. J Inflamm Res. 2024. PMID: 38481477 Free PMC article. - Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review).
Yu T, Jiang W, Wang Y, Zhou Y, Jiao J, Wu M. Yu T, et al. Int J Oncol. 2024 Apr;64(4):40. doi: 10.3892/ijo.2024.5628. Epub 2024 Feb 23. Int J Oncol. 2024. PMID: 38390935 Free PMC article. Review.
References
- Eshhar Z, Waks T, Bendavid A, Schindler DG. Functional expression of chimeric receptor genes in human T cells. J Immunol Methods. 2001;248(1-2):67–76. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 CA120409/CA/NCI NIH HHS/United States
- P30 AI045008/AI/NIAID NIH HHS/United States
- P30 CA016520/CA/NCI NIH HHS/United States
- R01 CA165206/CA/NCI NIH HHS/United States
- K08 CA166039/CA/NCI NIH HHS/United States
- 5R01 CA165206/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources